Loading...
Market
Will FDA approve new indications for Caplyta by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements, official press releases from Johnson & Johnson
Story
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6B at JPM25
Jan 13, 2025, 03:04 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies, a developer of treatments for central nervous system disorders, for approximately $14.6 billion. The deal, announced at the J.P. Morgan Healthcare Conference (JPM25) in San Francisco, marks the largest public biotech acquisition in over a year. Intra-Cellular Therapies' schizophrenia drug, Caplyta, is among the assets J&J will gain through this acquisition. The transaction is set to be completed within the year, with J&J offering $132 per share, a 39% premium over Intra-Cellular's closing stock price on the previous Friday. This move is seen as a strategic fit for J&J, aiming to bolster its growth in the neurosciences sector.
View original story
Similar markets
Two • 25%
None • 25%
Three or more • 25%
One • 25%
Increases by more than 10% • 25%
Remains within 10% of current share • 25%
Other • 25%
Decreases by more than 10% • 25%
No • 50%
Yes • 50%
Approved in both USA and EU • 25%
Approved in USA only • 25%
Not approved in USA or EU • 25%
Approved in EU only • 25%
